Faculty Opinions recommendation of Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.

2010 ◽  
Author(s):  
Juan Palou Redorta ◽  
Guillermo Urdaneta
Keyword(s):  
Bladder Cancer ◽  
Cancer Recurrence ◽  
Invasive Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Scoring Model ◽  
Bladder Cancer Recurrence ◽  
Nonmuscle Invasive Bladder Cancer

scholarly journals Impact of maintenance therapy using a half dose of the bacillus Calmette–Guérin Tokyo strain on recurrence of intermediate and high-risk nonmuscle invasive bladder cancer: a retrospective single-center study

BMC Urology ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Dai Koguchi ◽  
Kazumasa Matsumoto ◽  
Takahiro Hirayama ◽  
Shigetaka Moroo ◽  
Momoko Kobayashi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
High Risk ◽  
Maintenance Therapy ◽  
Cancer Recurrence ◽  
Invasive Bladder Cancer ◽  
Bacillus Calmette Guerin ◽  
Efficacy And Safety ◽  
Kaplan Meier ◽  
Half Dose ◽  
Nonmuscle Invasive Bladder Cancer

Abstract Background Data are scarce regarding intravesical maintenance therapy (MT) with the low-dose bacillus Calmette–Guérin (BCG) Tokyo strain. We investigated the efficacy and safety of MT with a half dose of the Tokyo strain for patients following transurethral resection of nonmuscle invasive bladder cancer (NMIBC). Methods This study retrospectively reviewed clinical data on 78 patients diagnosed with intermediate or high-risk NMIBC followed by either MT (n = 38) or IT alone (n = 40) between January 2012 and March 2018. Statistical analysis was performed to compare recurrence-free survival (RFS) and adverse effects between the two groups. BCG was instilled once weekly for 6 weeks as IT, then once weekly in 2-week for a total of 20 instillations over 3 years. Results Kaplan–Meier analyses showed that patients undergoing MT had significantly better RFS than did those undergoing IT alone (hazard ratio (HR):0.32, 95% confidence interval (CI):0.12–0.89, P = 0.02). The 3-year RFS was 65.0% in the IT group and 89.5% in the MT group. Multivariate analysis showed that MT was associated with a reduced risk of recurrence (HR: 0.32, 95% CI:0.11–0.93, P = 0.03). One MT patient (2.6%) exhibited progression. Conclusions The BCG Tokyo strain showed acceptable efficacy and safety in patients undergoing MT; thus, it is a potential treatment for preventing bladder cancer recurrence.

HMOX1 is an Important Prognostic Indicator of Nonmuscle Invasive Bladder Cancer Recurrence and Progression

2011 ◽  
Vol 185 (2) ◽  
pp. 701-705 ◽  
Author(s):  
Min-Su Yim ◽  
Yun-Sok Ha ◽  
Isaac Yi Kim ◽  
Seok-Joong Yun ◽  
Yung Hyun Choi ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Recurrence ◽  
Prognostic Indicator ◽  
Invasive Bladder Cancer ◽  
Bladder Cancer Recurrence ◽  
Nonmuscle Invasive Bladder Cancer

Optimization of Nonmuscle Invasive Bladder Cancer Recurrence Detection Using a Urine Based FGFR3 Mutation Assay

2011 ◽  
Vol 186 (2) ◽  
pp. 707-712 ◽  
Author(s):  
Tahlita C.M. Zuiverloon ◽  
Stephen S. Tjin ◽  
Martijn Busstra ◽  
Chris H. Bangma ◽  
Egbert R. Boevé ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Recurrence ◽  
Invasive Bladder Cancer ◽  
Fgfr3 Mutation ◽  
Mutation Assay ◽  
Bladder Cancer Recurrence ◽  
Nonmuscle Invasive Bladder Cancer
Sign in / Sign up

Export Citation Format

Share Document